samedan logo

 
 
spacer
home > ict
PUBLICATIONS

International Clinical Trials

 
International Clinical Trials (ICT) is a specialist journal designed to provide global coverage of key topics pertinent to the clinical trials sector.

Published quarterly, the journal offers a platform of communication and information-sharing for executive and strategic decision makers, seeking out new trends and marketing opportunities, as well as putting a spotlight on the latest innovations coming to market. ICT is specifically designed to be of interest to those actively seeking to source services for improved efficiency in what is an increasingly competitive market.

Prompted by the synergies between trial operations and wider contract research and outsourcing issues, ICT joined forces with sister title European Pharmaceutical Contractor (EPC) in late-2015, in a move that brings added value to both brands. With EPC now an inserted edition within ICT, industry practitioners across these complementary subject areas now have unrivalled access to a wealth of shared views and analyses.
 
For further information please contact:

Advertising
George Briggs

Editorial
Joel Emmons

Connect with us on Twitter: follow @IntClinTrials

Read our publications on the go in the Samedan app for phones and tablets. You can download issues for offline reading, and our archives go as far back as 2008! Download for free on the App Store, GooglePlay, or Amazon.

   
 

Click here to view the digital version
of ICT


 


  Click here to view the digital version of
Medical Writing:
The Backbone of Clinical Development
 
 

 

ict
 
 
Featured in this issue
Risk-Based Monitoring
Risk-Based Monitoring and Real-World Data

A Decentralised Ecosystem

There is an appetite for change in the capture, integration, and analysis of valuable data from human subjects, and Ian O’Shaughnessy at ICON explores the synergies between risk-based monitoring, decentralised clinical trials, and eSource.
Risk-Based Monitoring
Clinical Data Management and Quality

A Paradigm Shift in Data Monitoring

François Torche at CluePoints examines the impact of regulations on data quality and management, addressing the need for more optimised monitoring approaches in clinical data science.
  Therapeutic Focus: Dementia
Patient Registries in Dementia Trials

Early Detection for Invisible Patients

Professor Clive Ballard at the University of Exeter Medical School and Dr Dawie Wessels at Accelerated Enrollment Solutions discuss how patient registries can improve the detection of ‘invisible’ patients for dementia trials, presenting a new opportunity for prevention.

spacer


Published quarterly in
February, May,
August, and November




 


Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

 
White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement